Otuska Extends Collaboration With Gelanea On Schizophrenia Drug Research
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical and American firm Galenea agreed to extend joint research and development of novel therapies for schizophrenia and other central nervous system diseases. The two companies started the collaboration in January 2005 and the new agreement extended the period from five years to six years. According to the agreement, Otsuka will pay as much as $75 million in research fees to Galenea. Galenea targets the relationship between calcineurin and CNS and is developing drug candidates to treat schizophrenia. (Click here for more - Japanese language
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.